BeiGene Initiates Global Phase 2 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Relapsed or Refractory Mature T-and NK-Cell Lymphomas
Equity Metals Reports First Assays from No. 3 North 2025 Expansion Drilling, Including 540 g/t AgEq over 3.5m, Silver Queen Property, BC
Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference
